The Motley Fool: Novo Nordisk has growth potential and dividend yield

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Novo Nordisk chair, board members to quit after dispute with top shareholder

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk ...

Wegovy maker Novo Nordisk's board slims down as directors quit

The Novo Nordisk Foundation owns 28.1% of the company's shares, but holds a three-quarter share of the voting rights, which ...

Long-time Novo Nordisk bull tapped to lead Wegovy maker’s IR division

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
Devdiscourse

Novo Nordisk's Battle to Keep Medicaid Coverage for Obesity Drug Wegovy Amid Rising Costs

Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...
TipRanks on MSN

Novo Nordisk’s Wegovy Pregnancy Study: Safety Insights and Market Impact

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...